Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedDec 07, 2025
DataAggregated Company Financials
Companies4
  • 7D-0.8%
  • 3M18.3%
  • 1Y33.2%
  • YTD26.9%

Last week, the Biotech industry hasn't moved much but Idorsia is up 17% in that time. As for the the longer term, the industry is up 33% over the past 12 months. Looking forward, earnings are forecast to grow by 29% annually.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 07 Dec 2025CHF 2.0bCHF 343.6m-CHF 10,514,000.008.7x-189.8x5.8x
Tue, 04 Nov 2025CHF 1.9bCHF 343.6m-CHF 10,514,000.007.7x-179.8x5.5x
Thu, 02 Oct 2025CHF 1.7bCHF 344.3m-CHF 15,083,000.008.1x-115.5x5.1x
Sat, 30 Aug 2025CHF 1.8bCHF 383.4m-CHF 57,057,000.008x-32.4x4.8x
Mon, 28 Jul 2025CHF 2.1bCHF 333.9m-CHF 44,705,000.009x-47.7x6.4x
Wed, 25 Jun 2025CHF 1.9bCHF 333.9m-CHF 44,705,000.007.7x-41.7x5.6x
Fri, 23 May 2025CHF 1.8bCHF 333.9m-CHF 44,705,000.007.1x-40.5x5.4x
Sun, 20 Apr 2025CHF 1.6bCHF 411.1mCHF 65.6m4.7x24.8x4x
Tue, 18 Mar 2025CHF 1.7bCHF 409.3m-CHF 35,110,868.005.2x-47.9x4.1x
Thu, 13 Feb 2025CHF 1.9bCHF 330.3m-CHF 75,131,868.003.1x-25.7x5.9x
Sat, 11 Jan 2025CHF 1.8bCHF 330.3m-CHF 75,131,868.002.6x-24.5x5.6x
Mon, 09 Dec 2024CHF 1.6bCHF 330.9m-CHF 87,805,465.001.5x-17.8x4.7x
Wed, 06 Nov 2024CHF 1.9bCHF 331.2m-CHF 86,988,629.001.7x-22.3x5.9x
Fri, 04 Oct 2024CHF 1.5bCHF 333.1m-CHF 82,023,629.001.8x-18.1x4.5x
Sun, 01 Sep 2024CHF 1.4bCHF 323.4m-CHF 89,161,264.001.9x-16.1x4.4x
Tue, 30 Jul 2024CHF 791.2mCHF 151.7m-CHF 146,197,264.001.5x-5.4x5.2x
Thu, 27 Jun 2024CHF 749.0mCHF 151.7m-CHF 146,197,264.001.5x-5.1x4.9x
Sat, 25 May 2024CHF 542.4mCHF 170.5m-CHF 131,456,132.061x-4.1x3.2x
Mon, 22 Apr 2024CHF 427.2mCHF 67.2m-CHF 172,334,939.500.08x-2.5x6.4x
Wed, 20 Mar 2024CHF 326.5mCHF 67.1m-CHF 173,304,458.820.2x-1.9x4.9x
Fri, 16 Feb 2024CHF 403.3mCHF 55.5m-CHF 173,238,973.761.1x-2.3x7.3x
Sun, 14 Jan 2024CHF 342.8mCHF 317.4m-CHF 176,081,805.000.6x-1.9x1.1x
Tue, 12 Dec 2023CHF 324.5mCHF 318.0m-CHF 209,114,520.00n/a-1.6x1x
Thu, 09 Nov 2023CHF 276.9mCHF 318.4m-CHF 211,156,048.00n/a-1.3x0.9x
Sat, 07 Oct 2023CHF 258.0mCHF 318.4m-CHF 213,345,607.00n/a-1.2x0.8x
Mon, 04 Sep 2023CHF 317.3mCHF 318.5m-CHF 188,742,399.00n/a-1.7x1x
Wed, 02 Aug 2023CHF 415.1mCHF 323.4m-CHF 180,119,710.00n/a-2.3x1.3x
Fri, 30 Jun 2023CHF 314.8mCHF 331.8m-CHF 180,929,405.00n/a-1.7x0.9x
Sun, 28 May 2023CHF 326.8mCHF 332.8m-CHF 183,369,210.00n/a-1.8x1x
Tue, 25 Apr 2023CHF 436.5mCHF 480.7mCHF 8.2m1.6x53.3x0.9x
Thu, 23 Mar 2023CHF 424.0mCHF 497.1mCHF 11.5m1.5x36.8x0.9x
Sat, 18 Feb 2023CHF 480.8mCHF 493.4mCHF 14.5m1.6x33.2x1x
Mon, 16 Jan 2023CHF 512.3mCHF 493.4mCHF 14.5m1.7x35.3x1x
Wed, 14 Dec 2022CHF 505.4mCHF 493.4mCHF 14.5m1.7x34.9x1x
Price to Earnings Ratio

34.9x


Total Market Cap: CHF 505.4mTotal Earnings: CHF 14.5mTotal Revenue: CHF 493.4mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average -17.4x202320242025
Current Industry PE
  • Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 3.5x is lower than the industry's current PS ratio of 5.8x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 11% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.65%
Healthcare1.52%
Biotech-0.81%
Biotech-0.81%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
IDIA IdorsiaCHF 3.7416.5%
+CHF 132.4m		270.2%PS4x
BSLN Basilea PharmaceuticaCHF 51.605.2%
+CHF 31.3m		28.2%PE8.7x
MOLN Molecular PartnersCHF 3.395.9%
+CHF 7.1m		-33.0%PB1.3x
SANN Santhera Pharmaceuticals HoldingCHF 12.200%
CHF 21.2k		51.7%PS3.3x

Latest News

IDIA
CHF 3.74
Idorsia
7D
16.5%
1Y
270.2%

IDIA: Hypertension And Insomnia Portfolio Will Likely Fail To Justify Current Price

Analysts have modestly raised their price target on Idorsia, citing a slightly lower perceived risk profile and a marginally stronger long term profit outlook that supports a small increase in fair value, now estimated at approximately 2.00. What's in the News Reaffirmed 2025 guidance, projecting QUVIVIQ net sales around CHF 130 million, partnered business US-GAAP EBIT of about CHF 165 million, and a global US-GAAP operating loss of roughly CHF 55 million, mainly driven by the amended Viatris deal (corporate guidance).
SANN
CHF 12.20
Santhera Pharmaceuticals Holding
7D
0%
1Y
51.7%
MOLN
CHF 3.39
Molecular Partners
7D
5.9%
1Y
-33.0%
BSLN
CHF 51.60
Basilea Pharmaceutica
7D
5.2%
1Y
28.2%
KURN
CHF 30.64
Kuros Biosciences
7D
-4.3%
1Y
56.5%

Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts

Oct 18
Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts
RLF
CHF 2.79
Relief Therapeutics Holding
7D
-4.3%
1Y
-26.2%